^
Association details:
| Biomarker: | BRAF positive |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1118P - Real-world treatment patterns and outcomes among patients with BRAF+ metastatic melanoma refractory to first-line immunotherapy
Published date:
10/16/2023
Excerpt:
Patients on 2L IO had improved median OS compared to those who received 2L TT (27.2 vs 10.5 months; p<0.0001) as well as improved time to next progression at 1 (32 vs 11%) and 2 years (23 vs 2%)….Outcomes among patients with 1L IO-refractory BRAF+ MM are poor and many patients progress on 2L therapy. While 2L IO appeared to lead to more durable treatment responses for some patients, 2L TT was associated with a similar TTPD despite patients having more severe disease.
